Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Multi-Center Dose Escalation, Safety and Tolerability Study of AKN-028 in Patients With Acute Myelogenous Leukemia (AML)

NCT01573247 is registered in ClinicalTrials.gov with Akinion Pharmaceuticals AB as lead sponsor.

NCT NCT01573247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01573247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Multi-Center Dose Escalation, Safety and Tolerability Study of AKN-028 in Patients With Acute Myelogenous Leukemia (AML)
Lead sponsor
Akinion Pharmaceuticals AB
Phase
Phase 1/2
Overall status
Terminated
Start date
December 31, 2011
Completion date
March 31, 2016
Enrollment
25 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia